City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Anthony Stein, MD  
Search results:  13  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-13 Trials Jump to page:

COH Protocol Number: 17240

Principal Investigator: Anthony Stein, MD
Sponsor: Institutional

Title:  Single Patient IND for RB for the Use of AG-221 in the Treatment of AML

COH Protocol Number: 17228 ClinicalTrials.gov Number: NCT02675452

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

COH Protocol Number: 17227 ClinicalTrials.gov Number: NCT03224819

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 673 Administered as Short Term Intravenous Infusions in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

COH Protocol Number: 17226 ClinicalTrials.gov Number: NCT03245424

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  Expanded Access Program for Ivosidenib (AG-120) Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation

COH Protocol Number: 17195

Principal Investigator: Anthony Stein, MD
Sponsor: Institutional

Title:  Single Patient IND of Open-Label AG-120 in a Patient, UW, with Advanced Acute Myeloid Leukemia

COH Protocol Number: 17146 ClinicalTrials.gov Number: NCT03113643

Principal Investigator: Anthony Stein, MD
Sponsor: Institutional

Title:  Phase 1 Study of SL-401 in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia (AML) or in Treatment-Naive Subjects with AML Not Eligible for Standard Induction Therapy or in Subjects with High-Risk Myelodysplastic Syndrome (MDS)

COH Protocol Number: 17123

Principal Investigator: Anthony Stein, MD
Sponsor: Institutional

Title:  Single Patient IND Treatment for CS Using Ruxolitinib for the Treatment of Chronic Sclerodermatous-Like Graft-Versus-Host Disease

COH Protocol Number: 17098 ClinicalTrials.gov Number: NCT03173248

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects >= 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

COH Protocol Number: 15429 ClinicalTrials.gov Number: NCT02677922

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects with Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy

COH Protocol Number: 15333 ClinicalTrials.gov Number: NCT02632708

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

COH Protocol Number: 15123 ClinicalTrials.gov Number: NCT02520427

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

COH Protocol Number: 14012 ClinicalTrials.gov Number: NCT02094794

Principal Investigator: Anthony Stein, MD
Sponsor: NCI Approved External Peer Review

Title:  Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) Given in Combination with Cyclophosphamide and Etoposide as Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with High-Risk Acute Lymphocytic or Myelogenous Leukemia

COH Protocol Number: 13474 ClinicalTrials.gov Number: NCT02113982

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

 
Results per page: 25 50 100 All 1-13 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.